Navigation Links
Takeda Drives Leading PAMES Study in Brazil Showing Improved Symptom Relief for People with Erosive Gastroesophageal Reflux Disease (GERD)
Date:12/12/2013

ZURICH, December 12, 2013 /PRNewswire/ --

- First Head to Head Study Showed Tecta® As Effective for Healing and Complete Remission of Erosive GERD with Significantly Higher Symptom Relief After 8 Weeks compared to Esomeprazole[1] -

Takeda Pharmaceuticals International GmbH (Takeda) announced today results showing pantoprazole magnesium 40 mg (Tecta®) was as effective as esomeprazole 40 mg for achieving complete remission (defined as combined endoscopic healing and symptomatic relief) and the mucosal healing rate was high, whilst providing significantly higher symptom relief after 8 weeks.[1] Results of this Brazilian study, PAMES (Pantoprazole Magnesium x Esomeprazole), published today in the international medical journal, Alimentary Pharmacology and Therapeutics, provide further evidence to support the effectiveness of Tecta® in the management of erosive GERD, a condition which affects 10-30% of people around the world.[2]

Led by one of Brazil's principal medical research institutes, University of São Paulo Medical School, PAMES is the first head to head study which compares complete remission, healing and symptom relief of the proton-pump inhibitors (PPIs) pantoprazole magnesium 40 mg (Tecta®) with that of esomeprazole in patients with erosive GERD.[1]

"It is crucial that we have options which are effective for the treatment of erosive GERD, but symptom relief is also extremely important as the condition can have a damaging impact on the quality of patient lives," said Lead Investigator and gastroenterologist Professor Joaquim Moraes-Filho. "We hope these robust results will prompt stronger consideration of options for the management of symptom-reli
'/>"/>

SOURCE Takeda Pharmaceuticals International GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Advisory Committee Recommends Approval of Takedas Investigational Biologic Vedolizumab
2. Takedas Deerfield Campus Among Chicago Tribunes 2013 Top 100 Workplaces
3. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
4. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
5. Takeda Cares Day Raises $63,700
6. Takedas Deerfield Campus Ranked Among 2013 Working Mother 100 Best Companies
7. Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto lendpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
8. Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
9. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
10. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
11. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... VG Energy, a subsidiary of Viral Genetics, Inc. ... that it has retained alternative energy producer BioProcess ... for the development of commercial production of its potential ... with results reproduced multiple times from test-tube to small-pond ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... for the District of Delaware has ruled that Watson,s ... United States Patent No. 6,264,981 (the ,981 Patent).  The ... and would evaluate all available options, including an appeal. ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... proliferation of endogenous neural precursor cells cannot alone ... From the perspective of neural plasticity, Dr. Yun ... China observed the effects of functional electrical stimulation ... expression of basic fibroblast growth factor and epidermal ... infarct side. The researchers found that functional electrical ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... (XMRV) has been the subject of many studies since ... an unclear picture of XMRV,s role in human disease. ... issue of The Journal of Infectious Diseases , ... between XMRV and prostate cancer but not other links ...
... TUESDAY, Oct. 12 (HealthDay News) -- Women who maintain certain ... if a close relative has had the disease, a new ... healthy weight and drinking alcohol in moderation, if at all, ... breast cancer in postmenopausal women, the researchers said. "Whether ...
... Phase-II trial investigating a new, targeted therapy for metastatic ... reported at the 35th Congress of the European Society ... cancers affect the tissue lining the inner surfaces of ... In cases of metastatic disease, median survival is approximately ...
... can lead some women to wonder if the risk is ... 85,000 postmenopausal women, published in BioMed Central,s open access journal ... maintaining a healthy weight, and drinking less alcohol lowers breast ... of the disease. The University of Rochester Medical Center ...
... Gardner HealthDay Reporter , MONDAY, Oct. 11 ... in a U.S.-government-approved study involving human embryonic stem cells ... saving cells. The patient, being cared for at ... a spinal cord injury. The center specializes in treating ...
... lead some people to wonder if their risk is out ... postmenopausal women observed that regular physical activity, maintaining a healthy ... women with, and without a family history of the disease. ... Oct. 12, 2010, by the journal Breast Cancer Research ...
Cached Medicine News:Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Three Healthy Habits Cut Breast Cancer Risk, Study Finds 2Health News:Three Healthy Habits Cut Breast Cancer Risk, Study Finds 3Health News:Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2
... Massive hemorrhage associated with displaced pelvic fractures ... faced by orthopaedic and trauma surgeons. , ... antishock garment, external fixation, and internal fixation ... Stabilizer has been developed as a method ...
The large External Fixator consists of rods, clamps, and pins. It has multiple external fixation frames, independent pin placement, and MR safe clamps. The modular frame construction permits fracture...
The DFS Standard Fixator advantages include a highly adjustable system, modular compression/distraction, versatile central body component that provides 360 of rotation, and a positive locking mechani...
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: